Financial Results - Standalone (Q1 FY2026)

Quarter Ended June 30, 2026:

  • Revenue from operations: ₹924.42 crore
  • Other income: ₹61.63 crore (includes ₹18.00 crore dividend from Biddle Sawyer Limited)
  • Total income: ₹986.05 crore
  • Total expenses: ₹648.07 crore
  • Profit before tax: ₹337.98 crore
  • Tax expense: ₹84.65 crore (Current tax: ₹81.35 crore, Deferred tax: ₹3.30 crore)
  • Net profit: ₹253.33 crore
  • Basic and diluted EPS: ₹14.95

Comparative Performance:

  • Q1 FY2026 vs Q1 FY2025: Revenue increased 14.9% from ₹804.83 crore, net profit increased 23.7% from ₹204.70 crore
  • Q1 FY2026 vs Q4 FY2026: Revenue decreased 6.6% from ₹989.15 crore, net profit decreased 7.9% from ₹274.94 crore

Financial Results - Consolidated (Q1 FY2026)

Quarter Ended June 30, 2026:

  • Revenue from operations: ₹938.44 crore
  • Other income: ₹43.76 crore
  • Total income: ₹982.20 crore
  • Total expenses: ₹659.75 crore
  • Profit before tax: ₹322.45 crore
  • Tax expense: ₹85.27 crore (Current tax: ₹81.97 crore, Deferred tax: ₹3.30 crore)
  • Net profit: ₹237.18 crore
  • Basic and diluted EPS: ₹14.00

Management Changes

Resignation:

  • Mr. Subesh Williams (DIN: 07786724), Non-Executive Director, resigned effective closing hours of business on August 3, 2026 due to other professional commitments.

Appointments:

  • Ms. Karine J F Natland appointed as Non-Executive Director effective August 3, 2026 or upon obtaining DIN, whichever is later. She is SVP Asia Pacific at GSK, joined in 2024, previously worked at Organon, Merck and MSD. Holds executive dual MBA and bachelor's degree in pharmacy. Based in Singapore. Not related to existing directors and holds no shares in the company.

Re-appointment:

  • Mr. Bhushan Akshikar (DIN: 09112346) re-appointed as Managing Director for two years effective December 1, 2026. He has been MD since 2022, with 30+ years in pharmaceutical industry including previous roles at Janssen, Johnson & Johnson. Holds MBA in Marketing and Bachelor's in Pharmaceutical Sciences. Also director of Biddle Sawyer Limited. Holds no shares and not related to existing directors.

Dividend Information

  • Final dividend of ₹57 per equity share for FY2026 approved by shareholders at Annual General Meeting held on June 30, 2026.

Subsidiary Information

  • Biddle Sawyer Limited is a 100% subsidiary
  • Received dividend of ₹18.00 crore from subsidiary in Q1 FY2026
  • Subsidiary contributed revenues of ₹17.79 crore and net profit of ₹1.84 crore for Q1 FY2026

Audit Information

  • Financial results reviewed by Audit Committee and approved by Board on August 3, 2026
  • Limited review conducted by Deloitte Haskins & Sells LLP (Firm Registration No. 117366W/W-100018)
  • Review partner: Rajiv Shah (Membership No. 112878)
  • Review conducted under SRE 2410 standards

Segment Information

  • Company has only one reportable segment: Pharmaceuticals
  • No separate segment disclosures required

Meeting Details

  • Board meeting held on August 3, 2026 from 1:00 PM to 3:35 PM
  • Meeting included review of Q1 FY2026 financial results and management changes